Updated:
Optimi Health Corp.
Optimi Health Corp. is a Canadian public company licensed to supply psilocybin, MDMA, and other psychedelics for clinical trials and therapeutic research.
Optimi Health Corp.
Optimi Health Corp. was incorporated as a corporation with a focus on becoming a licensed producer of controlled psychedelic substances under Health Canada's regulations. Co-founded by Bill Ciprick, Dane Stevens, and others, the company went public on the Canadian Securities Exchange in 2021. Its business model centers on cultivating, processing, and supplying GMP-grade psilocybin, MDMA, and psilocin for clinical trials and therapeutic applications. The firm's strategy involves partnering with research institutions and biopharma companies conducting psychedelic-assisted therapy studies. Optimi has established supply agreements and collaborations, including with the University of British Columbia for a psilocybin trial in alcohol use disorder. The company targets the North American market, particularly Canada and the United States, where regulatory pathways for psychedelics are advancing. Optimi employs approximately 20 staff and operates a single facility in Princeton, British Columbia. In March 2023, the company received its Drug Establishment Licence from Health Canada, allowing it to manufacture and sell psychedelic substances for research. The firm has not disclosed team size or additional offices; it maintains an online presence via its corporate website and social media channels. A structural differentiator is Optimi's focus exclusively on regulated psychedelic production under Health Canada's framework, positioning it as a supplier rather than a clinic operator. This model reduces direct patient exposure and aligns with GMP standards required by clinical trial sponsors. The company's public listing provides transparency but also subjects it to market volatility.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Does Optimi Health Corp. operate clinical trials or only supply substances?
Optimi is primarily a supplier of psychedelic substances to research institutions and biopharma companies. It does not operate its own clinical trial sites but collaborates with partners conducting studies, such as the University of British Columbia's psilocybin trial for alcohol use disorder.
What regulatory approvals does Optimi hold?
Optimi holds a Drug Establishment Licence (DEL) from Health Canada, as of March 2023. This licence permits the production, packaging, and sale of psilocybin, MDMA, and other controlled substances for research purposes under the Narcotic Control Regulations.
How does Optimi differentiate from other psychedelic producers?
Optimi focuses exclusively on producing GMP-grade psychedelics for research and therapeutic supply, rather than operating clinics or retail dispensaries. Its Health Canada DEL positions it among the few licensed players in Canada that can commercially distribute controlled psychedelics.
Who are the founders of Optimi Health Corp.?
Optimi was co-founded by Bill Ciprick and Dane Stevens, along with other early stakeholders. Bill Ciprick serves as a director, while Dane Stevens has held the role of CEO. Their backgrounds span life sciences, finance, and regulatory affairs.
What is Optimi's public listing status?
Optimi Health Corp. is publicly traded on the Canadian Securities Exchange under the ticker symbol OPTI and on the OTCQX in the U.S. under OPTHF. This structure provides access to capital markets but requires public disclosure of financials and operations.
Which specific psychedelic compounds does Optimi produce?
Optimi produces psilocybin, psilocin, and MDMA, all under its Health Canada licence. The company emphasizes synthesis and extraction methods to achieve GMP-compliant purity for clinical trial use.
Does Optimi have partnerships with pharmaceutical companies?
Optimi has disclosed a partnership with the University of British Columbia for a psilocybin clinical trial. It has also engaged in supply discussions with various biopharma firms, but specific commercial agreements remain limited in public filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: